相似文献
1
AD vaccines: conclusions and future directions.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):160-6. doi: 10.2174/187152709787847289.
2
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
Brain Struct Funct. 2010 Mar;214(2-3):201-18. doi: 10.1007/s00429-009-0236-2. Epub 2009 Dec 10.
3
Alternative Abeta immunotherapy approaches for Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27. doi: 10.2174/187152709787847306.
4
Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):88-97. doi: 10.2174/187152709787847315.
5
Amyloid-beta immunotherapy for Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017.
6
Amyloid-beta immunisation for Alzheimer's disease.
Lancet Neurol. 2008 Sep;7(9):805-11. doi: 10.1016/S1474-4422(08)70170-4. Epub 2008 Jul 28.
7
Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):82-7. doi: 10.2174/187152709787847270.
8
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. doi: 10.2174/187152709787847298.
9
Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):144-59. doi: 10.2174/187152709787847324.
10
Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):98-113. doi: 10.2174/187152709787847333.
引用本文的文献
1
Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.
Neurobiol Dis. 2020 Jun;139:104823. doi: 10.1016/j.nbd.2020.104823. Epub 2020 Feb 28.
2
Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
Alzheimers Res Ther. 2019 Dec 17;11(1):107. doi: 10.1186/s13195-019-0556-2.
3
Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
Mol Ther. 2017 Jan 4;25(1):153-164. doi: 10.1016/j.ymthe.2016.10.002.
4
A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.
Alzheimers Dement. 2015 Oct;11(10):1246-59. doi: 10.1016/j.jalz.2015.06.1884. Epub 2015 Jul 17.
5
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.
J Neuropathol Exp Neurol. 2012 May;71(5):362-81. doi: 10.1097/NEN.0b013e31825018f7.
6
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques.
PLoS One. 2011 Apr 19;6(4):e19110. doi: 10.1371/journal.pone.0019110.
7
Neuronal death in Alzheimer's disease and therapeutic opportunities.
J Cell Mol Med. 2009 Nov-Dec;13(11-12):4329-48. doi: 10.1111/j.1582-4934.2009.00889.x. Epub 2009 Sep 1.
本文引用的文献
1
Forecasting the global burden of Alzheimer's disease.
Alzheimers Dement. 2007 Jul;3(3):186-91. doi: 10.1016/j.jalz.2007.04.381.
2
Recent developments in Alzheimer's disease therapeutics.
BMC Med. 2009 Feb 19;7:7. doi: 10.1186/1741-7015-7-7.
3
Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE.
J Alzheimers Dis. 2009;17(1):59-68. doi: 10.3233/JAD-2009-1045.
4
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology.
J Neurosci. 2009 Feb 11;29(6):1846-54. doi: 10.1523/JNEUROSCI.5715-08.2009.
5
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.
Eur J Nucl Med Mol Imaging. 2009 May;36(5):811-22. doi: 10.1007/s00259-008-1039-z. Epub 2009 Jan 14.
6
Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.
Vaccine. 2009 Feb 11;27(7):957-64. doi: 10.1016/j.vaccine.2008.12.012. Epub 2008 Dec 27.
7
The coming of age of virus-like particle vaccines.
Biol Chem. 2008 May;389(5):521-36. doi: 10.1515/bc.2008.064.
8
Structural classification of toxic amyloid oligomers.
J Biol Chem. 2008 Oct 31;283(44):29639-43. doi: 10.1074/jbc.R800016200. Epub 2008 Aug 22.
9
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
Lancet. 2008 Jul 19;372(9634):216-23. doi: 10.1016/S0140-6736(08)61075-2.
10
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging.
J Neurosci Res. 2008 Sep;86(12):2784-91. doi: 10.1002/jnr.21713.
Zotero 插件